Since only RR-MS patients were included in this study, long-term follow-up of our patient cohort would be of interest to evaluate the HLA-DRB5*null genotype as a risk factor for secondary progressive MS. This evidence concerns the gene HLA-DRB5 and myeloid sarcoma.